Hims & Hers Health, Inc. $HIMS Shares Bought by Clear Street Group Inc.

Clear Street Group Inc. raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 23.6% during the 4th quarter, Holdings Channel reports. The firm owned 1,904,294 shares of the company’s stock after purchasing an additional 363,893 shares during the quarter. Hims & Hers Health comprises 0.2% of Clear Street Group Inc.’s investment portfolio, making the stock its 25th biggest holding. Clear Street Group Inc.’s holdings in Hims & Hers Health were worth $61,832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after purchasing an additional 283 shares in the last quarter. W.G. Shaheen & Associates DBA Whitney & Co lifted its stake in Hims & Hers Health by 4.8% in the 3rd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock valued at $436,000 after buying an additional 350 shares in the last quarter. BAM Wealth Management LLC grew its holdings in Hims & Hers Health by 5.6% during the 4th quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock valued at $240,000 after buying an additional 393 shares during the last quarter. Xponance Inc. grew its holdings in Hims & Hers Health by 1.5% during the 3rd quarter. Xponance Inc. now owns 28,195 shares of the company’s stock valued at $1,599,000 after buying an additional 419 shares during the last quarter. Finally, Captrust Financial Advisors increased its position in Hims & Hers Health by 3.1% during the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock worth $728,000 after buying an additional 443 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Michael Chi sold 97,289 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer owned 407,282 shares of the company’s stock, valued at $10,055,792.58. This represents a 19.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 36,922 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80. Following the transaction, the chief financial officer owned 281,867 shares in the company, valued at approximately $7,300,355.30. The trade was a 11.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 212,807 shares of company stock valued at $5,473,644 in the last three months. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Trading Down 7.0%

Shares of Hims & Hers Health stock opened at $26.85 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The firm has a market cap of $6.21 billion, a PE ratio of -298.33, a P/E/G ratio of 50.32 and a beta of 2.37. The business’s fifty day moving average is $25.41 and its two-hundred day moving average is $26.83. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.20 EPS. Analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on HIMS shares. Leerink Partners boosted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Morgan Stanley dropped their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.70.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.